Snapshot from Aug 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Codis Acquires Catalent Nottingham Facility
Business acquisition

Codis Acquires Catalent Nottingham Facility

Analysis based on 7 articles · First reported Aug 03, 2026 · Last updated Aug 03, 2026

Sentiment
20
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition strengthens Combined DNA Index System' competitive position in the European CDMO market, potentially increasing its market share and revenue. Catalent's divestiture of the Nottingham facility may streamline its portfolio and focus on core operations, though the financial terms were not disclosed.

Pharmaceutical Contract Manufacturing Biopharmaceuticals
Event Summary

Combined DNA Index System, a global contract development and manufacturing organization (CDMO) specializing in spray drying and amorphous solid dispersions, announced the successful closing of its acquisition of Catalent's Nottingham, UK facility on August 3, 2026. The acquisition adds oral solid dose development and small-scale commercial manufacturing capabilities, expanding Combined DNA Index System' integrated spray dry offering in Europe. Combined with Combined DNA Index System' commercial-scale PSD-4 investment in Haverhill, UK, the acquisition establishes the region's most comprehensive spray dry pathway from development to commercial intermediates and final dose forms. The Nottingham team brings over two decades of formulation and clinical supply expertise. Matthew Streeter, General Manager of the newly acquired site, has been appointed to the Combined DNA Index System executive team. The acquisition strategically complements Combined DNA Index System' large-scale commercial spray drying facility in Haverhill, which is undergoing expansion with a new GEA Pharma-SD PSD-4 commercial spray dryer scheduled for validation in 2027.

Key Actions
100 Combined DNA Index System acquired Catalent
Entities Involved
priv
Combined DNA Index System
Combined DNA Index System is the acquirer, expanding its European spray drying capabilities and integrating the Nottingham facility to offer end-to-end services. This acquisition enhances its competitive position and growth prospects.
Importance 100.0 Sentiment 70.0
stock
Catalent
Catalent divested its Nottingham facility, streamlining its portfolio and potentially focusing on higher-growth areas. The sale may generate proceeds but reduces its UK manufacturing footprint.
Importance 80.0 Sentiment 40.0
cnt
United Kingdom
The United Kingdom is the location of the acquired facility and Combined DNA Index System' Haverhill site, benefiting from increased CDMO investment and job retention in the region.
Importance 40.0 Sentiment 30.0
per
Nicolas Fortin
As CEO of Combined DNA Index System, Nicolas Fortin led the acquisition and welcomed the Nottingham team, signaling strategic leadership and commitment to growth.
Importance 30.0 Sentiment 50.0
per
Matthew Streeter
Matthew Streeter, General Manager of the acquired Nottingham site, was appointed to the Combined DNA Index System executive team, playing a key role in integrating the new facility.
Importance 20.0 Sentiment 50.0
per
Steve Facer
Steve Facer, SVP Sales & Marketing at Combined DNA Index System, highlighted the differentiated offering, supporting the strategic value of the acquisition.
Importance 15.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.